Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reports on a case where treatment-resistant giant unilateral Bowen’s disease of the scalp responded to radiotherapy, but provides no further clinical details or results.

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

This study reports that while primary treatment for uveal melanoma has a very high success rate, treating distant metastases, particularly in the liver, remains challenging. Tebentafusp, dependent on HLA-A expression, is the first drug to extend patient survival.

This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.

This review discusses nanoparticle-based topical delivery systems for treating skin diseases and presents no new clinical findings; it emphasizes natural polymer-based nanoparticles and future applications like targeted drug delivery.

This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

This review discusses medications used in dermatology, detailing their side effects and interactions, and reports no new clinical results.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

In this case study, a transition to the MEK inhibitor trametinib successfully stabilized disease and reduced toxicity in a patient with refractory kaposiform lymphangiomatosis after prolonged sirolimus and steroid treatment.

Results are not reported in this abstract, which notes that while Janus kinase inhibitors like baricitinib show therapeutic benefits for alopecia areata, the mechanisms and reliable predictors of response remain unclear.

In this case report, a young female Indian patient with alopecia areata saw hair regrowth within 2 months of treatment with oral tofacitinib, with continued improvements over a 5-month period and no reported side effects.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This narrative review reports that baricitinib, a first-generation JAK inhibitor, has shown effectiveness in treating alopecia areata and atopic dermatitis and holds promise for other chronic dermatoses, marking a significant advancement in dermatological immunotherapy according to the summarized findings.

This study found that treatment with baricitinib 4 mg over 52 weeks led to clinically meaningful regrowth of eyebrows and eyelashes in patients with alopecia areata, even without complete scalp hair regrowth.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

This case report describes a successful treatment of alopecia universalis in a 37-year-old female using oral tofacitinib, along with other therapies, resulting in significant hair regrowth without notable safety concerns.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This study found that oral baricitinib was more effective than methotrexate in treating severe alopecia areata, with significant improvements in SALT scores over six months.

This study examined dermoscopic features in African-American women with different types of alopecia and found that a perifollicular pink blush, potentially indicating inflammation, was common, particularly resolved with anti-inflammatory treatment, suggesting dermoscopy could aid in management.

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

CTP-543 is generally safe for treating alopecia areata.